Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2566390 | 0.76 | DRD3 (0.48) | — | |
| SCHEMBL835196 | 0.69 | — | — | |
| SCHEMBL9862148 | 0.69 | ADH1C (0.33) | SIGMAR1 | |
| SCHEMBL2565599 | 0.69 | SLC6A2 (0.36) | — | |
| SCHEMBL614355 | 0.67 | — | — | |
| SCHEMBL28282906 | 0.67 | — | — | |
| SCHEMBL1067943 | 0.65 | GRIN2B (0.33) | SIGMAR1 | |
| SCHEMBL27848169 | 0.65 | — | — | |
| SCHEMBL383574 | 0.65 | ADH1A (0.46) | SIGMAR1 | |
| SCHEMBL555985 | 0.64 | LTA4H (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149045-B2 | Raw material for vapor deposition including organoplatinum compound and vapor deposition method using the raw material for vapor deposition | TANAKA KIKINZOKU KOGYO K.K. (JP) | 2021-10-19 | — | — | US | disclosed |
| US-20200148713-A1 | RAW MATERIAL FOR VAPOR DEPOSITION INCLUDING ORGANOPLATINUM COMPOUND AND VAPOR DEPOSITION METHOD USING THE RAW MATERIAL FOR VAPOR DEPOSITION | TANAKA KIKINZOKU KOGYO K.K. (JP) | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148713-A1 | RAW MATERIAL FOR VAPOR DEPOSITION INCLUDING ORGANOPLATINUM COMPOUND AND VAPOR DEPOSITION METHOD USING THE RAW MATERIAL FOR VAPOR DEPOSITION | RNF168, IPO5, IPO4 | SIGMAR1 208/4885 |
| US-11149045-B2 | Raw material for vapor deposition including organoplatinum compound and vapor deposition method using the raw material for vapor deposition | RNF168, IPO5, IPO4 | SIGMAR1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.